CN104490882A - Traditional Chinese veterinary medicine for treating duck infectious serositis diseases and preparation method thereof - Google Patents
Traditional Chinese veterinary medicine for treating duck infectious serositis diseases and preparation method thereof Download PDFInfo
- Publication number
- CN104490882A CN104490882A CN201410702800.8A CN201410702800A CN104490882A CN 104490882 A CN104490882 A CN 104490882A CN 201410702800 A CN201410702800 A CN 201410702800A CN 104490882 A CN104490882 A CN 104490882A
- Authority
- CN
- China
- Prior art keywords
- florfenicol
- rifampicin
- herbal medicine
- duck
- infectious serositis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000272525 Anas platyrhynchos Species 0.000 title claims abstract description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 36
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 35
- 206010058556 Serositis Diseases 0.000 title claims abstract description 31
- 230000002458 infectious effect Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 63
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 claims abstract description 33
- 229960003760 florfenicol Drugs 0.000 claims abstract description 33
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims abstract description 33
- 229960001225 rifampicin Drugs 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229920003081 Povidone K 30 Polymers 0.000 claims abstract description 21
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 21
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 21
- 239000008213 purified water Substances 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000008118 PEG 6000 Substances 0.000 claims abstract description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims abstract description 4
- 201000010099 disease Diseases 0.000 claims description 32
- 241000411851 herbal medicine Species 0.000 claims description 28
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 12
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 244000144977 poultry Species 0.000 abstract description 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 244000144972 livestock Species 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241001478212 Riemerella anatipestifer Species 0.000 description 7
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 229940097572 chloromycetin Drugs 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 4
- 229960003053 thiamphenicol Drugs 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 125000005633 phthalidyl group Chemical group 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010071301 Perihepatitis Diseases 0.000 description 2
- 229930189077 Rifamycin Natural products 0.000 description 2
- 208000007893 Salpingitis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000008578 acute process Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- 230000008576 chronic process Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 208000008494 pericarditis Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229960003292 rifamycin Drugs 0.000 description 2
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000195622 Astasia Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a traditional Chinese veterinary medicine for treating duck infectious serositis diseases. The traditional Chinese veterinary medicine is prepared from the following raw materials in parts by weight: 5-10 parts of florfenicol, 1-5 parts of rifampicin, 8-15 parts of PEG 6000, 5-10 parts of PVP-K30, 5-10 parts of beta-cyclodextrin, 7-12 parts of tween-80, 15-25 parts of glycerol and 25-40 parts of purified water. The traditional Chinese veterinary medicine provided by the invention is easily available in raw material and low in price, is safe and does not have toxic or side effects on livestock and poultry bodies; and a preparation method of the traditional Chinese veterinary medicine, provided by the invention, is simple, easy to operate and suitable for large-scale production and popularization.
Description
Technical field
The invention belongs to veterinary drug technical field, be specifically related to a kind ofly treat herbal medicine of infectious serositis in duck disease and preparation method thereof.
Background technology
Infectious serositis in duck, also known as Riemerella anatipestifer infection, new duck disease, pest of duck syndrome or duck septicemia, is a kind of contagious infection disease caused by riemerella anatipestifer (RA).Be more common in duck in 2 one 7 week age clinically, in acute and chronic process, main manifestations is eye, nasal secretions, breathe, cough, dysentery, ataxia and head and neck tremble.The feature of pathological change is fibrinous pericarditis, cellulosic perihepatitis, cellulosic airsacculitis, cheesy salpingitis and arthritis.If not in time control or prevention and controls improper, duck group large quantities of morbidity death can be caused.For the control of this disease, the medicine that data is introduced is a lot of, but some medicines are due to life-time service, and make the pathogenic bacteria in duck body create Drug resistance, prevention effect is not ideal enough.Infectious serositis in duck, also known as Riemerella anatipestifer infection, new duck disease, pest of duck syndrome or duck septicemia, is a kind of contagious infection disease caused by riemerella anatipestifer (RA).Be more common in 2-7 duck in age in week clinically, in acute and chronic process, main manifestations is eye, nasal secretions, breathe, cough, dysentery, ataxia and head and neck tremble.The feature of pathological change is fibrinous pericarditis, cellulosic perihepatitis, cellulosic airsacculitis, cheesy salpingitis and arthritis.If not in time control or prevention and controls improper, duck group large quantities of morbidity death can be caused.For the control of this disease, the medicine that data is introduced is a lot of, but some medicines are due to life-time service, and make the pathogenic bacteria in duck body create Drug resistance, prevention effect is not ideal enough.
According to market feedback, duck oromeningitis is the contagious disease of a kind of main harm duckling caused by riemerella anatipestifer.Along with intensive, the scale of aquaculture and the fast development of industrialization level are throughout all parts of the country; the economic loss caused every year reaches several hundred million unit; there is effect worse and worse in anti-the curing the disease of current drug application; product of the present invention substantially increases the therapeutic effect of duck oromeningitis, thus decreases very large economic loss to aquaculture.
Summary of the invention
The object of the present invention is to provide a kind of herbal medicine for the treatment of infectious serositis in duck disease, this medicine can treat infectious serositis in duck disease, reduces duck to the drug resistance of medicine.
In order to achieve the above object, the present invention is by the following technical solutions:
The invention provides a kind of herbal medicine for the treatment of infectious serositis in duck disease, be made up of the raw material of following weight portion: florfenicol 5 ~ 10, rifampicin 1 ~ 5, PEG 6,000 8 ~ 15, PVP-K30 5 ~ 10, beta-schardinger dextrin-5 ~ 10, tween 80 7 ~ 12, glycerol 15 ~ 25 and purified water 25 ~ 40.
The herbal medicine of described treatment infectious serositis in duck disease is made up of the crude drug of following weight portion: florfenicol 6 ~ 10, rifampicin 3 ~ 5, PEG 6,000 10 ~ 13, PVP-K30 8 ~ 10, beta-schardinger dextrin-5 ~ 7, tween 80 9 ~ 12, glycerol 18 ~ 22 and purified water 25 ~ 30.
The herbal medicine of described treatment infectious serositis in duck disease is made up of the crude drug of following weight portion: florfenicol 10, rifampicin 5, PEG 6,000 12, PVP-K30 10, beta-schardinger dextrin-5, tween 80 12, glycerol 20 and purified water 26.
Described herbal medicine dosage form is granule.
The preparation method concrete steps of the herbal medicine of described treatment infectious serositis in duck disease are as follows:
(1), under stirring, under 45 ~ 65 DEG C of water-baths, add formula ratio purified water, PEG 6000, PVP-K30 and beta-schardinger dextrin-in container, stirring and dissolving obtains mixture a;
(2), under stirring, in mixture a, add formula ratio florfenicol and tween 80, be stirred to transparent, then add till formula ratio glycerol stirs and obtain mixture b;
(3) obtain dry powder by spray-dried for mixture b, add the obtained soft material of formula ratio rifampicin mixing in the most backward dry powder, pelletize, dries and get final product.
Herbal medicine dosage form of the present invention is granule, according to the needs of special circumstances, also can make the dosage form of the States Pharmacopoeia specifications such as powder, powder.
compared with prior art, the beneficial effect that obtains of the present invention:
The herbal medicine of florfenicol of the present invention and the composite system of rifampicin, crude drug is easy to get, cheap and safety, without any side effects to poultry body.Preparation method of the present invention is simple, easy to operate, is suitable for large-scale production and applies.
the present invention selects effect of raw material as follows:
Florfenicol: chemical name is that D (+)-Su-1-is to first vitriol base phenyl-2-two chloroethene phthalein amino-3-fluorine propanol, be the third generation chloromycetin extensive pedigree antibiotic of chemosynthesis, all have inhibitory action to multiple gram positive bacteria and gram negative bacteria.Antibacterial activity and the chloromycetin of florfenicol are closely similar, but because of in structure without para-position nitro without potential induced aplastic anemia effect.Therefore, the eighties in last century is by after Schering-Plough Developed, nineteen ninety in Japan's listing, then goes on the market, for cattle respiratory system disease, fish pasteurellosis bacillus, fish streptococcicosis etc. in states such as Norway, France, Britain, Austria, Mexico and Spain first.1999, florfenicol and the preparation thereof of the manufacturer production such as Zhong Mu Anda, Hubei pharmaceutcal corporation, Ltd were also approved for national two class novel chiral synthon, for the bacterial disease of the pig caused by sensitive organism, fowl and fish.Also go through as the feed additive of pig in Japan and Mexico, trade name is respectively Florocol and Nunor.In recent years, along with deepening continuously of research, the experimental study in pharmacokinetics, pharmacodynamics, toxicology etc. makes people have comprehensive understanding to this medicine.The Antibacterial Mechanism of florfenicol is identical with chloromycetin and thiamphenicol, mainly through acting on bacterial ribosome 505 subunit, suppressing second phthalidyl transferring enzyme, thus suppressing the extension of chain, the synthesis of interference bacterioprotein.Thiamphenicol and chloramphenicol resistance bacteria strain can produce the second phthalidyl transferring enzyme (Acetyl-transferase) propagated with plasmid usually; this enzyme can make-the OH in first vitriol mycin and chloromycetin structure on C-3 methyl position that the reaction of second phthaleinization occurs, and therefore loses pharmacologically active.Florfenicol is then because the-OH of C-3 position is replaced by-F, can not by the destruction of second phthalidyl transferring enzyme, so still responsive to florfenicol to the bacterial strain of thiamphenicol and chloramphenicol resistance, its antibacterial activity, higher than chloromycetin and thiamphenicol, so far florfenicol veterinary clinic is widely used.
On October 8th, 2002, the 1500 plumage 30 age in days eggs of raising in the feed lot of lane town one, Fengcheng City, Jiangxi Province are ill with duckling, and part sick duck spirit is depressed, and necking down is drowsiness, and edge is dug earth with the snout, and bipod is weak, is reluctant to walk about, crowded or heap.The 2d symptom of morbidity is even more serious, and spirit is extremely depressed, and starts to occur death.The sick duck had shakes all over when can not stand or stand, and again and again nods or swings, and turns over or swing to side after some healths.Ceaselessly to flap during struggle dipteron, pedal after two lower limbs.The loss of appetite that symptom is slightly light or absolutely useless, eye nose has serosity or emulsion sexual secretion, and cough, sneeze, feces is yellow green, is infectious serositis in duck through clinical definite.To October 12, ill duck is dead 70 plumages altogether.October 10, to October 12, successively carried out clinical treatment with gentamycin and enrofloxacin, and effect is not very desirable, and clinical death rate is about 50%.Started October 13 to treat with florfenicol, after the treatment of florfenicol drinking-water, mortality rate drops to 10% immediately, and the state of an illness obtains effective control, carries out clinical treatment have received good effect with florfenicol.
Rifampicin is the semisynthetic antibiotics of rifomycins, its chemistry 3 one (4 monomethyl 1 croak a crash formimino group) rifamycin by name.Usually this medicine is rufous crystalline powder, and slightly soluble in water, be easy to be dissolved in chloroform, be soluble in ethyl acetate and methanol, molecular weight is 822.95.Rifamycin produces primarily of gram positive bacteria alnycolatopsis.These antibiotic, except pathogen such as energy tuberculosis, leprosy etc., also find that they are effective to multiple pathogens.Rifampicin is semi-synthetic wide-spectrum bactericide, and with the beta subunit strong bonded of RNA polymerase depending on DNA, the synthesis of anti-bacteria RNA, prevents this enzyme to be connected with DNA, thus blocks rna transcription process.Because rifampicin easily produces drug resistance, present stage is except treatment tuberculosis and be used as except external eye drop, and rifampicin is cured a line medication from people and withdrawn to, and due to the characteristic of rifampicin, veterinary one line is just at the clinical efficacy of Devoting Major Efforts To Developing rifampicin.The has a broad antifungal spectrum of rifampicin, effective to multiple pathogens, but the application on present stage veterinary clinic need Devoting Major Efforts To Developing, and the novel formulation Development Level for rifampicin also has much room for improvement.In the research carrying out infectious serositis in duck, find that rifampicin has potent inhibitory action to inner Mo Shi bacillus clinically, for the feature of rifampicin poorly water-soluble, the granule that we adopt water solublity rifampicin that market is sold and florfenicol to make, has had good curative effect to duck oromeningitis.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further described, but do not limit content of the present invention.
embodiment 1
Treat a herbal medicine for infectious serositis in duck disease, be made up of the raw material of following weight portion: florfenicol 5 ~ 10, rifampicin 1 ~ 5, PEG 6,000 8 ~ 15, PVP-K30 5 ~ 10, beta-schardinger dextrin-5 ~ 10, tween 80 7 ~ 12, glycerol 15 ~ 25 and purified water 25 ~ 40.
The herbal medicine of described treatment infectious serositis in duck disease is made up of the crude drug of following weight portion: florfenicol 6 ~ 10, rifampicin 3 ~ 5, PEG 6,000 10 ~ 13, PVP-K30 8 ~ 10, beta-schardinger dextrin-5 ~ 7, tween 80 9 ~ 12, glycerol 18 ~ 22 and purified water 25 ~ 30.
The preparation method concrete steps of the herbal medicine of described treatment infectious serositis in duck disease are as follows:
(1), under stirring, under 45 ~ 65 DEG C of water-baths, add formula ratio purified water, PEG 6000, PVP-K30 and beta-schardinger dextrin-in container, stirring and dissolving obtains mixture a;
(2), under stirring, in mixture a, add formula ratio florfenicol and tween 80, be stirred to transparent, then add till formula ratio glycerol stirs and obtain mixture b;
(3) by spray-dried for mixture b, spray drying device arranges inlet temperature 180 DEG C of outlet temperatures 200 DEG C of spraying dry and obtains dry powder, and add the obtained soft material of formula ratio rifampicin mixing in the most backward dry powder, pelletize, dries and get final product.
embodiment 2
Treat a herbal medicine for infectious serositis in duck disease, be made up of the raw material of following weight portion: florfenicol 10, rifampicin 5, PEG 6,000 12, PVP-K30 10, beta-schardinger dextrin-5, tween 80 12, glycerol 20 and purified water 26.
The present embodiment preparation method is identical with the preparation method of embodiment 1.
embodiment 3
Treat a herbal medicine for infectious serositis in duck disease, be made up of the raw material of following weight portion: florfenicol 5, rifampicin 2, PEG 6,000 10, PVP-K30 7, beta-schardinger dextrin-6, tween 80 10, glycerol 25 and purified water 37.
The present embodiment preparation method is identical with the preparation method of embodiment 1.
embodiment 4
Treat a herbal medicine for infectious serositis in duck disease, be made up of the raw material of following weight portion: florfenicol 8, rifampicin 5, PEG 6,000 12, PVP-K30 10, beta-schardinger dextrin-7, tween 80 8, glycerol 22 and purified water 27.
The present embodiment preparation method is identical with the preparation method of embodiment 1.
embodiment 5
Treat a herbal medicine for infectious serositis in duck disease, be made up of the raw material of following weight portion: florfenicol 6, rifampicin 4, PEG 6,000 8, PVP-K30 5, beta-schardinger dextrin-10, tween 80 7, glycerol 15 and purified water 30.
The present embodiment preparation method is identical with the preparation method of embodiment 1.
embodiment 6
Treat a herbal medicine for infectious serositis in duck disease, be made up of the raw material of following weight portion: florfenicol 7, rifampicin 1, PEG 6,000 15, PVP-K30 9, beta-schardinger dextrin-5, tween 80 8, glycerol 25 and purified water 40.
The present embodiment preparation method is identical with the preparation method of embodiment 1.
embodiment 7
Treat a herbal medicine for infectious serositis in duck disease, be made up of the raw material of following weight portion: florfenicol 8, rifampicin 2, PEG 6,000 13, PVP-K30 7, beta-schardinger dextrin-6, tween 80 9, glycerol 18 and purified water 32.
The present embodiment preparation method is identical with the preparation method of embodiment 1.
embodiment 8
Treat a herbal medicine for infectious serositis in duck disease, be made up of the raw material of following weight portion: florfenicol 7.5, rifampicin 3.2, PEG 6,000 12.5, PVP-K30 6.8, beta-schardinger dextrin-9.5, tween 80 11, glycerol 19 and purified water 38.
The present embodiment preparation method is identical with the preparation method of embodiment 1.
embodiment 9
Treat a herbal medicine for infectious serositis in duck disease, be made up of the raw material of following weight portion: florfenicol 9.5, rifampicin 2.5, PEG 6,000 13.5, PVP-K30 5, beta-schardinger dextrin-8.2, tween 80 7.6, glycerol 21.5 and purified water 28.
The present embodiment preparation method is identical with the preparation method of embodiment 1.
embodiment 10
Treat a herbal medicine for infectious serositis in duck disease, be made up of the raw material of following weight portion: florfenicol 8.5, rifampicin 1.5, PEG 6,000 11.5, PVP-K30 7.8, beta-schardinger dextrin-8, tween 80 8.7, glycerol 19 and purified water 33.
The present embodiment preparation method is identical with the preparation method of embodiment 1.
test example
Experimental animal: according to epidemiology, clinical symptoms, pathology cuts open inspection, identification and isolation of pathogen comprehensive diagnos is duck oromeningitis, random selecting 880, be divided into 11 groups, often organize 80, the granule drinking-water that test group 1 ~ 9 adopts embodiment 2 ~ 10 to prepare successively is treated, matched group adopts commercially available pest of duck speed to go out, and blank group does not use any medicine, be used in conjunction 3 days, observe the curative effect also adds up healing, effective and invalid number, calculate cure rate, result of the test refers to following table 1.
Curative effect judging standard:
Cure: mental status is good, feed intake is normal, and feces detects without exception;
Effective: disease is clearly better;
Invalid: mental status is poor, draw white or faint yellow water sample to wash just, astasia, rocks on foot, and shed feathers phenomenon.
Conclusion: as can be seen from Table 1, the cure rate of test group 1 ~ 9 when treating chicken respiratory and infecting reaches more than 93%, and matched group is 64%.Statistical analysis shows, the cure rate of test group is significantly higher than matched group.Result of the test shows, granule prepared by the embodiment of the present invention 2 ~ 10 infects chicken respiratory and has good therapeutic efficiency.
Claims (5)
1. treat the herbal medicine of infectious serositis in duck disease for one kind, it is characterized in that, be made up of the raw material of following weight portion: florfenicol 5 ~ 10, rifampicin 1 ~ 5, PEG 6,000 8 ~ 15, PVP-K30 5 ~ 10, beta-schardinger dextrin-5 ~ 10, tween 80 7 ~ 12, glycerol 15 ~ 25 and purified water 25 ~ 40.
2. treat the herbal medicine of infectious serositis in duck disease according to claim 1, it is characterized in that, be made up of the crude drug of following weight portion: florfenicol 6 ~ 10, rifampicin 3 ~ 5, PEG 6,000 10 ~ 13, PVP-K30 8 ~ 10, beta-schardinger dextrin-5 ~ 7, tween 80 9 ~ 12, glycerol 18 ~ 22 and purified water 25 ~ 30.
3. treat the herbal medicine of infectious serositis in duck disease according to claim 1, it is characterized in that, be made up of the crude drug of following weight portion: florfenicol 10, rifampicin 5, PEG 6,000 12, PVP-K30 10, beta-schardinger dextrin-5, tween 80 12, glycerol 20 and purified water 26.
4. treat the herbal medicine of infectious serositis in duck disease according to claim 1, it is characterized in that described herbal medicine dosage form is granule.
5. according to any one of claims 1 to 3, treat the preparation method of the herbal medicine of infectious serositis in duck disease, it is characterized in that, concrete steps are as follows:
Under stirring, under 45 ~ 65 DEG C of water-baths, add formula ratio purified water, PEG 6000, PVP-K30 and beta-schardinger dextrin-in container, stirring and dissolving obtains mixture a;
Under stirring, in mixture a, add formula ratio florfenicol and tween 80, be stirred to transparent, then add till formula ratio glycerol stirs and obtain mixture b;
Obtain dry powder by spray-dried for mixture b, add the obtained soft material of formula ratio rifampicin mixing in the most backward dry powder, pelletize, dries and get final product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410702800.8A CN104490882A (en) | 2014-11-29 | 2014-11-29 | Traditional Chinese veterinary medicine for treating duck infectious serositis diseases and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410702800.8A CN104490882A (en) | 2014-11-29 | 2014-11-29 | Traditional Chinese veterinary medicine for treating duck infectious serositis diseases and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104490882A true CN104490882A (en) | 2015-04-08 |
Family
ID=52932398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410702800.8A Pending CN104490882A (en) | 2014-11-29 | 2014-11-29 | Traditional Chinese veterinary medicine for treating duck infectious serositis diseases and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104490882A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105560189A (en) * | 2016-01-22 | 2016-05-11 | 山东畜牧兽医职业学院 | Florfenicol slow-release dispersoid and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000072A1 (en) * | 1991-06-27 | 1993-01-07 | Richardson Vicks, Inc. | Process for solubilizing difficultly soluble pharmaceutical actives |
WO2005009429A1 (en) * | 2003-07-18 | 2005-02-03 | Idexx Laboratories, Inc. | Compositions containing prodrugs of florfenicol and methods of use |
CN102697730A (en) * | 2012-05-07 | 2012-10-03 | 郑州后羿制药有限公司 | Florfenicol soluble power and preparation method thereof |
CN102813627A (en) * | 2012-09-19 | 2012-12-12 | 上海同仁药业有限公司 | Preparation method of florfenicol soluble powder |
-
2014
- 2014-11-29 CN CN201410702800.8A patent/CN104490882A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993000072A1 (en) * | 1991-06-27 | 1993-01-07 | Richardson Vicks, Inc. | Process for solubilizing difficultly soluble pharmaceutical actives |
WO2005009429A1 (en) * | 2003-07-18 | 2005-02-03 | Idexx Laboratories, Inc. | Compositions containing prodrugs of florfenicol and methods of use |
CN102697730A (en) * | 2012-05-07 | 2012-10-03 | 郑州后羿制药有限公司 | Florfenicol soluble power and preparation method thereof |
CN102813627A (en) * | 2012-09-19 | 2012-12-12 | 上海同仁药业有限公司 | Preparation method of florfenicol soluble powder |
Non-Patent Citations (1)
Title |
---|
周昕: "复方氟苯尼考泡腾片的制备及对雏鸭浆膜炎的药效学研究", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105560189A (en) * | 2016-01-22 | 2016-05-11 | 山东畜牧兽医职业学院 | Florfenicol slow-release dispersoid and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102670516A (en) | Tilmicosin soluble powder and preparation method thereof | |
CN102940722B (en) | A kind ofly treat Chinese medicine composition of fowl bacterial disease and preparation method thereof | |
CN102973489B (en) | Florfenicol solid dispersoid and preparation method thereof | |
CN101417018B (en) | Preparation method of animal injection capable of clearing away the heat-evil and expelling superficial evils, cooling blood and relieving dysentery | |
CN105287790A (en) | Paederia scandens extract and applications thereof | |
CN106620668A (en) | Compound tilmicosin solid dispersing agent and preparation method thereof | |
CN104490882A (en) | Traditional Chinese veterinary medicine for treating duck infectious serositis diseases and preparation method thereof | |
CN103446312A (en) | Compound poplar flower oral liquid and preparation method thereof | |
CN104161761B (en) | A kind of compound oxytetracycline injection and preparation method thereof | |
CN106554385B (en) | Polypeptide compound and application thereof in livestock and poultry | |
CN104971041A (en) | Dinitolmide dry suspension and preparation method thereof | |
CN101874774A (en) | Suspension composition containing lysozyme and florfenicol and preparation method thereof | |
CN106362159A (en) | Molecular skeleton type tilmicosin sustained release preparation and preparation method thereof | |
CN103211818A (en) | Pharmaceutical composition for treating or preventing bacterial and mycoplasma diseases of livestock and use thereof | |
CN102847160B (en) | Compound quinolone injection for livestock, and preparation method thereof | |
CN101829129A (en) | Veterinary compound gentamycin sulfate injection and preparation method thereof | |
CN103705568A (en) | Compound levofloxacin hydrochloride soluble powder for treating respiratory diseases of poultry | |
CN109731044B (en) | Traditional Chinese medicine compound granule for treating intestinal infection of poultry and preparation method thereof | |
CN105560446A (en) | Medicinal preparation for preventing and curing mycoplasmosis of livestock and improving non-specific immunity and preparing method of medicinal preparation | |
CN108272788B (en) | Puerarin is in the drug and pig feed additive for preparing the purposes in the drug for preventing and treating pig virus infection, preventing and treating pig virus infection | |
CN106902147B (en) | Sophora flavescens powder and preparation method and application thereof | |
CN105232469A (en) | Thiamphenicol soluble powder and preparation method thereof | |
CN105748742A (en) | Pharmaceutical composition used for livestock and poultry dysentery and feed and preparation method thereof | |
CN105920165A (en) | Novel medicine preparation for efficiently preventing and treating pasteurellosis of livestock and poultry and preparation method thereof | |
CN105853511A (en) | Chinese herbal medicinal bait for preventing and controlling Ictalurus punctatus Edwardsiellasis, and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150408 |
|
RJ01 | Rejection of invention patent application after publication |